compounds are available for out licensing in either pre clinical stage or early in phase 1 trials. Tim doesn't harbour any thoughts/intentions ( according to his own interviews ) of progressing any candidates further than phase 1. The main caveat to out licensing all compounds would be an outright takeover by a major Pharma, which could be a distinct possibility imho. :o).
hey, I personally think Aurora+FLT3 is close to commercialization, and will follow the same footsteps as CHK1. But it all depends on whether the clinical trials were successful or not... If its successful and we go into human trials (like CHK1), then licensing deal is a big possibility. Keeping my fingers crossed.
dissecting John Reader's (not Reading) interview it is striking that he discusses TYK2 (today's announcement) and CHK1 (the licensing deal) but does not mention Aurora/FLT3 at all. He also uses the phrase at 6 minutes 40: "it's very important for Sareum to have these licensing events under our belt", note the plural "events". Perhaps nothing, perhaps everything. Perhaps we are closer to commercialising Aurora/FLT3... ? DYOR
Are looking to resurrect themselves through a policy of aggressively pursuing licensing deals for the best available compounds in the oncology field. Their lead compound is now PNT737 (CCT245737, Ex SAR) as highlighted on the ProNAi website. They wanted (and needed) the best available after their own compound PNT2258 was withdrawn from trials and the whole underlying DANi platform closed down including the Plymouth Michigan laboratories that supported the development. A total wipeout, hence share price collapse ensued. Cash in bank, buy your way back into the game but only buy the best. I hope they succeed as it will be all good for us pi,s here. :o).
I first traded this stock 9yrs ago. It was brought to my attention as one of those old pump n dump stocks through mass email campaigns. But I read into the company more and could see there was some decent potential. Probably made about 10-15k over the few years then I sold and the SP collapsed for a longggggg time. The share has been diluted a good fair bit over the years hence why 1p equals approx 30 million capitalisation. I was about to buy back in the day before it started it's rise from the lows. Missed out big time there but that's the AIM for you. Sitting on 50% profit in fracking but thinking SAR has really good potential even at this price. So can anyone tell me how much cash is in the bank ? Why does Pronai look like a dead duck on the Nasdaq ? I've researched the rest but these two questions remain unanswered after my due diligence. I do appreciate it's usually DYOR but this used to be a friendly board so I hope that remains the case.
agree completely the timing of today's announcement is odd. I suspect they wanted to give it some attention in its own right, rather than have it overshadowed by something else in the results. My personal view is Aurora + FLT3 will be snapped up for a combo trial with a BTK inhibitor. but that is my informed guess.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.